CAS 1360460-82-7

Anlotinib Dihydrochloride

Description:

Anlotinib dihydrochloride is a small molecule tyrosine kinase inhibitor primarily used in the treatment of various cancers, including non-small cell lung cancer and soft tissue sarcoma. It functions by inhibiting multiple receptor tyrosine kinases, which are involved in tumor growth and angiogenesis. The compound is characterized by its ability to interfere with signaling pathways that promote cancer cell proliferation and survival. Anlotinib dihydrochloride is typically administered orally and is known for its favorable pharmacokinetic profile, which includes good bioavailability and a manageable half-life. The dihydrochloride form enhances its solubility and stability, making it suitable for pharmaceutical formulations. Common side effects associated with its use may include hypertension, fatigue, and gastrointestinal disturbances, reflecting its mechanism of action on vascular endothelial growth factor receptors and other kinases. Overall, Anlotinib dihydrochloride represents a significant advancement in targeted cancer therapy, offering a novel approach to managing malignancies resistant to conventional treatments.

1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)cyclopropanamine dihydrochloride

CAS: 1360460-82-7

1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)cyclopropanamine dihydrochloride

Purity: 98%

Molecular weight: 480.37g/mol

Ref: 54-PC1005914

N/A

CAS: 1058156-90-3, 1360460-82-7

Formula: C₂₃H₂₂FN₃O₃HCl

Molecular weight: 407.45 2* 36.46

Ref: 4Z-A-322002

Anlotinib Dihydrochloride

CAS: 1360460-82-7

Anlotinib is a drug that belongs to a class of drugs called kinase inhibitors. It has been shown to inhibit tumor growth by targeting the epidermal growth factor receptor (EGFR) and the c-kit receptor. Anlotinib also inhibits proliferation in vitro, induces apoptosis, and suppresses tumour growth in vivo. In addition, Anlotinib can be used as a monotherapy or in combination with other anti-cancer agents such as hydrochloric acid, cyclophosphamide, and paclitaxel. The clinical studies show that it may have a prognostic value for patients with advanced solid tumours.

Formula: C₂₃H₂₂FN₃O₃·2HCl

Purity: Min. 95%

Molecular weight: 407.44 g/mol

Ref: 3D-KEC46082